Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Life Sciences' CEO Joins BIO CEO & Investor Conference 2017 Panel
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Appoints International Alzheimer's Expert to Scientific Advisory Board
The AXA-UPMC Chair is hosted within the highly specialized Institute for Memory and Alzheimer’s Disease After a post-doctoral fellowship focused on structural and functional neuroimaging of the healthy aging (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Development 844-689-3939 Email: info@anavex.com Investors: 866-505-2895 Email: ir@anavex.com Media
- Anavex Presents at AD/PD 2017 Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media Dobson Media Group 203-258-0159 dennisdobsonjr@dobsonmediagroup.com
- Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC
Anavex remains dedicated to advancing ANAVEX 2-73 and will be reporting new data to investors as it becomes (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most anavex.com Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 mhaines@rivereastir.com Media
- Anavex Life Sciences to Present at the 30th Annual ROTH Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media: Clayton
- Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:
- Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application with Expanding Claims
About Rett Syndrome Rett syndrome is a devastating, non-inherited genetic post-natal progressive neurodevelopmental (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media
- Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development: Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:
- Anavex Life Sciences Reports New Data Demonstrate the Neuroprotective Features of Sigma-1 Receptor
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media
- Anavex Life Sciences to Present at the 31st Annual ROTH Conference 2019
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Investors & Media:
- Anavex Announces 2-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response
(Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated projected in any of such statements due to various factors, including the risks set forth in the Company’s most Thomas Jenene Thomas Communications, LLC 908- 938-1475 Email: JTC@jenenethomascommunications.com Media
